Additionally, pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, has been associated with an elevated bladder cancer risk, prompting caution in clinical guidelines, yet exhibits promising effects in cancers of the breast, lung, and colon [10]. This evidence concerns the gene PPARG and urinary bladder carcinoma.